GDP与CHOP方案治疗非特异性外周T 细胞淋巴瘤的临床对比研究

目的:探讨GDP与CHOP方案治疗非特异性外周T细胞淋巴瘤的临床疗效,为临床治疗提供参考。方法:选择2013年1月到2016年1月我院收治的非特异性外周T细胞淋巴瘤患者80例,随机分为GDP组(n=40)和CHOP组(n=40)。GDP组患者给予GDP治疗方案(顺铂+吉西他滨+强的松),CHOP组患者给予CHOP治疗方案(多柔比星+环磷酰胺+长春新碱+强的松),两组患者均治疗6个疗程。比较两组患者临床疗效和不良反应发生情况。结果:GDP组患者近期疗效总有效率为75.00%,明显高于CHOP组的45.00%,差异具有统计学意义(P0.05)。GDP组患者的无进展生存期(PFS)、总生存期(OS)分别为(9.69±1.50)月和(16.72±3.06)月,明显大于CHOP组的(5.16±1.38)月和(10.98±3.37)月,差异具有统计学意义(P0.05)。GDP组患者恶心呕吐的发生率为72.50%,明显低于CHOP组的97.50%,差异具有统计学意义(P0.05)。结论:GDP方案治疗非特异性外周T细胞淋巴瘤的临床疗效明显优于CHOP方案,且不良反应发生率低,值得在临床上推广应用。

Clinical Comparative Study of GDP and CHOP Regimen in Treatment of Nonspecific Peripheral T Cell Lymphoma

Objective:To study the clinical efficacy of GDP and CHOP in the treatment of nonspecific peripheral T cell lymphoma,and to provide reference for clinical treatment.Methods:Selected 80 cases of patients with nonspecific peripheral T cell lymphoma who treated in our hospital from January 2013 to January 2016,and randomly were divided into GDP group(n=40) and CHOP group (n=40).The GDP group were treated with the GDP regimen (cisplatin+gemcitabine+prednisone), and the CHOP group were treatment with the CHOP regimen (adriamycin+cyclophosphamide+vincristine+prednisone), the patients in two groups were treated for six courses. Compared the clinical efficacy and adverse reactions of patients in the two groups.Results:The total effective rate in the short-term of the GDP group was 75.00%, which was significantly higher than 45.00% of the CHOP group, the difference was statistically significant (P<0.05). The progression-free survival (PFS) and overall survival (OS) of the GDP group were (9.69± 1.50) months and (16.72± 3.06) months respectively, which were significantly higher than (5.16± 1.38) months and (10.98± 3.37) months of the CHOP group,the differences were statistically significant(P<0.05). The incidence of nausea and vomiting in GDP group was 72.50%, which was significantly lower than 97.50% of CHOP group, and the difference was statistically significant (P<0.05).Conclusion:The clinical efficacy of GDP regimen on the treatment of patients with nonspecific peripheral T cell lymphoma is superior to that of traditional CHOP regimen, and have less adverse reactions, which is worthy application in clinic.